Alembic Pharmaceuticals Limited — Updates, 12-11-2024: Press Release

Alembic Pharmaceuticals has received USFDA Final Approval for its Ivabradine Tablets in 5 mg and 7.5 mg dosages. This approval is significant as Ivabradine is indicated for reducing hospitalization risks due to worsening heart failure in adult patients with stable, symptomatic chronic heart failure and reduced left ventricular ejection fraction. The estimated market size for Ivabradine Tablets is approximately US$ 145.3 million for the twelve months ending September 2024, according to IQVIA. With this approval, Alembic now totals 218 ANDA approvals, comprising 192 final and 26 tentative approvals, thereby enhancing its portfolio and potential market reach. Investors may view this development favorably as it strengthens the company’s presence in the cardiovascular medication space, highlighting a positive outlook for growth in this therapeutic area.